Roche: Most Of Avastin Business In Europe Is Now Gone

Follows Competition From Biosimilar Bevacizumab Since Last Summer

Roche_White_Logo
Amgen and Pfizer were the first moves on biosimilar Avastin in the EU • Source: Shutterstock

More from Biosimilars

More from Products